Race, socioeconomic status, and other prognostic factors for survival from colo-rectal cancer

Dayal, Hari H.; Polissar, Lincoln; Chen, Yang; Dahlberg, Steve

doi:10.1016/0021-9681(87)90185-8

Cited by 78 publications

(70 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In striking contrast to studies that demonstrated an association between nonwhite race and inferior cancer care and, ultimately, unfavorable long-term survival, [14][15][16][17][18][19][20][21] we observed that nonwhite race predicted improved surgical care, as defined by adequate lymph node evaluation. Because African Americans and Hispanics tend to be uninsured and of lower socioeconomic status, it is possible that university centers are the likely providers of their surgical care: These findings are contrary to popular opinion.…”

Section: Discussioncontrasting

confidence: 99%

Variations in gastric cancer care

Al‐Refaie

Virnig

Tseng

et al. 2009

Cancer

View full text Add to dashboard Cite

BACKGROUND:Race is associated with patterns of presentation and survival outcomes of gastric cancer in the United States. However, the impact of race on the receipt of guideline‐recommended care is not well characterized. By using current recommendations, the authors examined the association between race and guideline‐recommended treatments and identified factors that are predictive of variations in gastric cancer care.METHODS:By using the National Cancer Database for 1998 through 2005, 106,002 patients with gastric adenocarcinoma were identified. Multivariate analysis techniques were used to examine the association between race, the receipt of guideline‐recommended care, and survival after adjusting for covariates.RESULTS:Although African‐American and Hispanic patients were more likely to undergo adequate lymphadenectomy (≥15 lymph nodes) and to receive care at comprehensive cancer centers and high‐volume facilities (for all, P ≤ .001), they were less likely to receive adjuvant multimodality therapy for American Joint Committee on Cancer stage IB through IV, lymph node‐negative (M0) disease. Up to 60% of all patients who underwent gastrectomy failed to receive adequate lymphadenectomy and adjuvant multimodality therapy. The delivery of multimodality therapy varied significantly by stage and lymph node evaluation (P ≤ .001). These findings persisted on our multivariate analyses, indicating that African‐American and Hispanic patients received adequate lymph node evaluation (P ≤ .001), whereas they were associated with receiving no adjuvant multimodality therapy (P ≤ .025).CONCLUSIONS:There were significant variations in treatment for gastric cancer among ethnic groups in the United States. It was noteworthy that, although nonwhite race was associated with improved surgical care, gastric cancer care remained suboptimal overall. Cancer programs need to identify procedures to maximize the delivery of adequate gastric cancer care to all patients. Cancer 2010. © 2010 American Cancer Society.

show abstract

Section: Discussioncontrasting

confidence: 99%

Variations in gastric cancer care

Al‐Refaie

Virnig

Tseng

et al. 2009

Cancer

View full text Add to dashboard Cite

show abstract

“…For the 12 studies that met the inclusion and exclusion criteria, [28][29][30][31][32][33][34][35][36][37][38][39] information was abstracted and recorded on a structured information collection form by 1 investigator (T.E.M.) and was verified by another investigator (X.L.D.).…”

Section: Study Identificationmentioning

confidence: 99%

“…We used a ruler to estimate the HR and 95% CI, assuming that the figure was drawn to scale. Dayal et al 29 reported a P value <.001 rather than a 95% CI for the HR, so we calculated a conservative estimate for the 95% CI assuming a P value of .001. Although Akerley and colleagues did not report an HR adjusted for SES, they stated in the text that adding SES to the model did not change the HR.…”

Section: Study Identificationmentioning

confidence: 99%

“…[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] Only a handful of studies have addressed racial disparities in survival for colon cancer by adequately incorporating both treatment and SES 31,33,35,37 in addition to factors like cancer stage, tumor grade, and comorbid conditions. Among this limited number of studies, [28][29][30][31][32][33][34][35][36][37][38][39] the findings have been inconsistent. One of the main reasons for these inconsistent findings may be that previous studies had relatively small numbers of study patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Meta‐analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer

Meyer

Franzini

2007

Cancer

100

View full text Add to dashboard Cite

Patients with cystic fibrosis (CF) often experience acute pulmonary exacerbations (APE) and may be treated with a wide variety of intravenous antibiotics. The aim of this review is to provide an evidence‐based summary of pharmacokinetic/pharmacodynamic (PK/PD), tolerability, and efficacy studies utilizing the intravenous (IV) polymixin antibiotic colistimethate sodium (CMS) in the treatment of APE and to identify areas where further study is warranted. Currently, there is not an international standard on the labeling of CMS products. As a result, this has lead to confusion in the interpretation of the literature with respect to efficacy, tolerance, and optimal dosing strategy. The dosing ranges of IV CMS from the literature are 5.3–12.9 mg/kg/day, maximum 480 mg per day for 60 kg patient (Colomycin® injection‐European product) and 8–21.3 mg/kg/day, maximum 800 mg per day for 60 kg patient (Coly‐Mycin M® parenteral‐US product).The literature supports a CMS dose of 8 mg/kg/day divided every 8 hr (maximum 480 mg/day) for the treatment of APE secondary to Pseudomonas aeruginosa. The maximum recommended CMS dose of 480 mg/day is less than is recommended by the FDA‐approved and CFF dosing guidelines but in agreement with UK CF Trust Antibiotic Working Group recommendations. There is debate over the frequency of CMS administration (once daily vs. thrice‐daily) and its impact on resistance and clinical efficacy. Further study is needed to determine the tolerability and efficacy of extended‐interval dosing of CMS in the treatment of APE. Pediatr Pulmonol. 2013; 48:1–7. © 2012 Wiley Periodicals, Inc.

show abstract

“…Empirical results have been contradictory. In some studies, racial differences have disappeared after controlling for social class; this has been observed in breast cancer Bassett & Krieger, 1986;Stavraky et al, 1987;Gordon et al, 1992) and in prostate cancer Dayal et al, 1985). The reverse pattern has been reported in colorectal cancer: controlling for race abolished social class differences (Dayal et al,1'987).…”

Section: Artifactual Explanationsmentioning

confidence: 98%